Meet the mentors of the of the Henri Termeer Network. To inquire about becoming a mentor, click here.

Jeff Albers

Jeff Albers

Jeff Albers served as CEO and President of Blueprint Medicines in Cambridge, MA from 2014-2022 and recently transitioned into the role of Executive Chairman of the Board of Directors. He also currently serves on the Board of Directors of Magenta Therapeutics and Kymera Therapeutics and is on the board of advisors of Life Science Cares. Jeff has more than 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases.

In 2014, he joined Blueprint Medicines as Chief Executive Officer and led the research-stage company through a crossover financing and initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including two FDA-approved therapies and a rapidly advancing pipeline.

Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, Jeff held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), most recently as vice president of the U.S. hematology and oncology business unit. After several years in Corporate Development roles at Genzyme, Jeff was called to Henri’s office to meet with Henri and Peter Wirth, where they unexpectedly offered him a position as the head of the U.S. transplant business. Jeff views this moment as a critical inflection point in his career as these two mentors were clearly willing to “take a chance” on him and place him in a role that would expand and accelerate his career growth. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo.

Jeff holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.

Areas of Expertise: Corporate Strategy, Financing/IR; Company Building,HR/Recruiting/Talent; Commercial; Partnering / BD.

Mike Bonney

Mike Bonney

Mike Bonney is a business executive with over 30 years of biotech and pharmaceutical expertise. Bonney was CEO and Director of Cubist Pharmaceuticals from 2003 until 2014. Under his leadership, Cubist grew from a struggling micro-cap to the world’s leading antibiotic company and was acquired by Merck early in 2015 for $9.5 billion. Prior to Cubist, Bonney was Vice President of Sales and Marketing at Biogen where he built the company’s commercial infrastructure for the launch of its first product. Before joining Biogen, he spent 11 years at Zeneca Pharmaceuticals in a range of commercial, operating, and strategic roles, ending his career there as National Business Director.

Bonney chairs the boards of Alnylam Pharmaceuticals, Kaleido Biosciences and Magenta Therapeutics. He is a member of several other boards, including Bristol Myers Squibb. Bonney spends much of his time identifying and mentoring the next generation of life science leaders.

Bonney was a regional winner and national finalist (2013) in the life science segment of Ernst & Young’s Entrepreneur of the Year and was one of six executives nationwide named as Marketwatch’s CEO of the Year (2011). He received his undergraduate degree in economics from Bates College.

Mike and his family have a wide range of philanthropic interests including education – Mike chaired the Board of Bates College from 2010 – 2019; the Gulf of Maine Research Institute, where the Bonney’s focus is on sustainable economic activity in the rapidly changing Gulf of Maine, with a specific focus on shellfish and seaweed aquaculture; and Rare, an international NGO focused on inspiring change, so people and nature thrive.

Areas of expertise: Company, team and board building; executive and leadership development; succession planning; corporate and non-profit governance; capital raising; strategic planning.

Katherine Bowdish

Katherine Bowdish

Kathy Bowdish is a business and scientific leader with a passion for cutting-edge science, strategy and execution. Kathy is President & CEO of PIC Therapeutics, a venture-backed precision-medicine oncology focused company.

Prior to Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies. Past positions include President & CSO, Permeon Biologics; Co-founder, President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals; Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.

Prior to Sanofi, Kathy co-founded or led several early-stage life science companies focused on biological therapies. Past positions include President & CSO, Permeon Biologics; Co-founder, President & CEO, Anaphore; President, Alexion Antibody Technologies and Senior Vice President, Alexion Pharmaceuticals; Founder, CEO & CSO, Prolifaron, prior to its acquisition by Alexion.

Kathy is the management representative on the Board of PIC Therapeutics, and on the Board of Adocia, a France based diabetes company. She previously served on the Board of Directors of MyoKardia, Warp Drive Bio, Portal Instruments, Thermalin, Permeon Biologics, Anaphore and Prolifaron, and as an Observer on the DiCE Molecules Board.

Kathy received a Ph.D. in molecular genetics from Columbia University College of Physicians and Surgeons in the City of New York, and a B.S. degree from the College of William and Mary.

Areas of Expertise: Early-stage company building; leadership, strategy, and execution; R&D; business development and partnering.

John Butler

John Butler

John Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders.

From 1997 to 2011, John held various positions at Genzyme. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. John also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche.

He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He was a member of the board of directors of Relypsa, Inc. a company developing a first in class treatment for hyperkalemia in patients with CKD, and served as Chairman of the Board at Keryx Biopharmaceuticals, a commercial stage company developing innovative products for people with renal disease. Additionally, he served as the chairman of the American Kidney Fund board of trustees from 2013-2015. The AKF is the leading patient focused charitable organization in kidney disease providing assistance to one in 5 patients on kidney dialysis in the US.

John received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.

Areas of Expertise: commercial strategy, business development, alliance management, and company building.

Daniel De Boer

Daniel De Boer

Daniel De Boer is Founder and Chief Executive Officer of ProQR Therapeutics. After one of his children was diagnosed with a rare disease, he started ProQR to develop RNA therapies for rare diseases. Under Daniel’s leadership ProQR developed a platform that yielded a diversified pipeline of potential treatments for rare diseases, and raised approximately $400M in funding, including an IPO on Nasdaq. Before founding ProQR, Daniel was founder and Chief Executive Officer of several technology companies. Daniel is also co-founder and strategic advisor to Amylon Therapeutics and Wings Therapeutics, strategic advisor at Frame Therapeutics, Meatable and Algramo, and a member of the board of advisors at The Termeer Foundation. In 2018 Daniel was named "Emerging Entrepreneur of the Year" by EY. In 2019 Daniel was selected for the Young Global Leader program at the World Economic Forum.

Daniel met Henri in late 2011, after stalking him for months to get a meeting. Six months later they co-founded ProQR Therapeutics. Daniel had the privilege of working closely with Henri as a board member in the years after and benefit from his mentorship in building ProQR.

Areas of Expertise: Company initiation and building; Fundraising private and public, including IPO; Building patient-centric organization.

Eli de los Pinos

Eli de los Pinos

Eli de los Pinos is the founding CEO of Aura, which she created from the ground up: She developed the company concept collaborating with Lasker award winner Dr. John Schiller at the National Cancer Institute and spearheaded fundraising efforts, raising a total of $140M in multiple rounds of financing. Prior to founding Aura, she worked in Eli Lilly & Co.’s oncology business unit, where she was part of the leadership team responsible for the market launch in Europe of Alimta, a drug for the treatment of lung cancer. Earlier in her career, Eli worked as a post-doctoral fellow at the Institute of Cancer Research in London. She previously completed fellowships at the Mount Sinai School of Medicine Institute of Molecular Medicine and at the Georgetown School of Medicine. Eli holds a Ph.D., magna cum laude, in Molecular Biology from the University of Barcelona and an MBA from IE Business School.

She is a member of the board of overseers at the Museum of Science, Boston. Eli has also been named to Boston Business Journal's “Top 40 under 40” list; as a Mass High Tech “Woman to Watch”; as a “Technology Pioneer” by the World Economic Forum; and as one of Goldman Sachs’ “100 Most Intriguing Entrepreneurs”.

Eli first met Henri in 2010 right after moving to Boston from Spain to start Aura. As a first time female CEO, Eli was privileged to have Henri’s mentorship in those early and challenging years guiding her to define the company’s strategy and Board of Directors, actively participating in her seed round of angel investors and in every financing round thereafter, introducing her to his closest business network and later becoming a Board member and key strategic advisor.

Areas of Expertise: Fundraising: Angel/Family Office and Venture Capital; Company Creation; General Management; Business Strategy; Research and Development: Rare Diseases, Oncology & Ophthalmology

Katherine Bowdish

Deborah Dunsire, M.D.

Dr. Deborah Dunsire, is President and CEO at H. Lundbeck A/S, the only global biopharmacaeutical company singularly focused on restoring brain health so every person can be their best.

A physician, trained in South Africa, she has over three decades of leadership in biotech, from large companies to start-ups.A physician, trained in South Africa, she has over three decades of leadership in biotech, from large companies to start-ups.

In 2005 she was appointed CEO of Millennium Pharmaceuticals and successfully moved the company as it delivered outstanding growth in oncology and inflammatory disease. The company was ultimately acquired by Takeda to be the foundation of its businesses in oncology and inflammatory disease. Deborah joined the board of that company in Japan and built the global oncology franchise for Takeda. Post leaving Takeda, she was CEO at neuroscience-focused FORUM Pharmaceuticals and at the inflammation and oncology focused start-up company, XTuit Pharmaceuticals.

She was CEO at Millennium Pharmaceuticals when she met Henri Termeer. He was gracious to welcome and include a new CEO in the Boston/Cambridge Biotech cluster. He was passionate about bringing transformation to the lives of patients with rare diseases and was a fierce competitor in business but always gracious in his dealings with people, whether in his own company or outside. Deborah was privileged to count Henri Termeer as a personal friend and, after he left Genzyme, a mentor.

Prior to moving to Boston to take the role with Millennium, Deborah spent 17 years at Novartis, working in South Africa, Switzerland and New Jersey, where she led the oncology business for the company.

She currently sits on the boards of Ultragenyx, with prior board experience at Millennium, Takeda Pharmaceuticals in Japan, Syros and Allergan Pharmaceuticals, where she served alongside Henri Termeer.

Areas of Expertise: Corporate strategy; R&D transformation and pipeline strategy; commercial and launch excellence; people and team development; accessing external innovation through partnerships and M&A; financing for growth; building diverse and inclusive high performing teams.

Roch Doliveux

Roch Doliveux

Roch Doliveux is currently Chairman of the Board of Directors for Pierre Fabre Group and Oxford Biomedica, as well as Chairman of the GLG Healthcare Institute. He is also a member of the board of directors at UCB and Stryker Corp. He also chairs the Caring Entrepreneurship Fund, a philanthropic initiative which he created in 2008 and which supports entrepreneurship in health and wellness.

Roch previously served as CEO at UCB, a position he held for more than a decade. Under his CEO tenure at UCB, Doliveux transformed the company from a diversified chemical group to a focused global biopharmaceutical leader. Prior to joining UCB, he held positions at Schering-Plough Corp., including President of Schering-Plough International, and at Ciba-Geigy (now Novartis).

Roch has a Doctor in Veterinarian Medicine from Maisons-Alfort (France), and he is Laureate of the Faculty of Medicine, Créteil, and holds an MBA with distinction from INSEAD (France). Doliveux was awarded the Doctor Honoris Causa degree of the University of Liège (Belgium) in and was bestowed the title of Commander of the Order of the Crown by the Belgian government.

Areas of Expertise: - experienced global biopharma CEO over 10 years - Experienced chairman of Boards over 4 years - Maximising potential of talents and teams - Interface between science and business - Company transformation and M&A

Mark Enyedy

Mark Enyedy

Mark Enyedy joined ImmunoGen in 2016 as President and Chief Executive Officer, bringing over twenty-five years of combined general management, business development and legal experience in the biotechnology industry. He joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio.

Previously, Mark served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mark was an associate with the Boston law firm Palmer & Dodge.

Mark serves on the Board of Directors of LogicBio, Inc., Ergomed plc, and The American Cancer Society of Eastern New England.

Mark holds a J.D. from Harvard Law School and a B.S. from Northeastern University.

Areas of Expertise: M&A; Oncology Development and Commercialization; Corporate Strategy; Transformation; General Management.

Jim Geraghty

Jim Geraghty

Jim Geraghty is an industry leader with over 30 years experience helping guide the development and commercialization of innovative therapies for rare diseases. He chairs the boards of Orchard Therapeutics, and of Idera and Pieris Pharmaceuticals, and serves on the boards of Voyager and Fulcrum Therapeutics and Idera.

Jim was earlier an entrepreneur-in-residence at Third Rock Ventures, a leading biotech venture fund, and a senior vice president for strategy and business development at Sanofi. Jim spent over 20 years at Genzyme, where he led Genzyme Europe and international development, and was founding president and CEO of Genzyme Transgenics. Jim started his career in strategy consulting at Bain.

A graduate of the Yale Law School, he holds an M.S. from the University of Pennsylvania and a B.A. from Georgetown.

Areas of Expertise: Company building, mentoring leaders, and governance.

Jeff Albers

Michael Gilman, Ph.D.

Michael is CEO of Arrakis Therapeutics. In addition, Mike currently serves on the Boards of Directors of Novartis Venture Fund, Obsidian Therapeutics, and Scholar Rock (NASDAQ: SRRK) and on the Scientific Advisory Board of FutuRx. Previously, Mike was Chief Executive Officer of Obsidian Therapeutics, a venture-funded company focused on applying synthetic biology to gene and cell therapies.

Prior to Obsidian, Mike was Founder and Chief Executive Officer of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. From 2012-2013, Mike served as Senior Vice President, Early-Stage Pipeline, at Biogen Idec, with responsibility for managing the company’s development programs through clinical proof-of-concept. He joined Biogen Idec in March 2012 following its acquisition of Stromedix, a venture-funded company focused on fibrosis and organ failure, where he was Founder and Chief Executive Officer.

Prior to founding Stromedix in 2006, Mike served as Executive Vice President, Research at Biogen Idec, with responsibility for the company’s discovery research activities in Cambridge and San Diego. From 1994 to 1999, Mike was at ARIAD Pharmaceuticals, where he was Executive Vice President and Chief Scientific Officer. From 1986 to 1994, Mike was on the scientific staff of Cold Spring Harbor Laboratory in New York, where his research focused on mechanisms of signal transduction and gene regulation.

Mike was a postdoctoral fellow with Dr. Robert Weinberg at the Whitehead Institute. He holds a PhD in Biochemistry from University of California, Berkeley, and a SB in Life Sciences from Massachusetts Institute of Technology.

Areas of Expertise: Company creation, team building, research and corporate strategy, partnering, financing, communication.

Ed Kaye

Ed Kaye

Ed Kaye, a pediatric neurologist, is the chief executive officer and a director of Stoke Therapeutics. Ed previously served as CEO of Sarepta Therapeutics, where he led the successful push to win FDA approval of Exondys 51, a pioneering drug for Duchenne muscular dystrophy. Before taking on the CEO role at Sarepta, he served as the company’s chief medical officer for six years, leading the drive to develop Exondys 51. He also served on Sarepta’s board of directors. Earlier in his career, Ed spent 10 years at Genzyme Corporation, most recently as group vice president of clinical development, where he supervised clinical research in programs focused on lysosomal storage disease and genetic neurological disorders. At Genzyme, Ed also held various roles, including vice president of medical affairs for lysosomal storage diseases, vice president of clinical research and interim head of PGH global medical affairs.

Starting at Genzyme, Ed had an opportunity to work with and importantly learn from Henri Termeer. After starting the position as CEO of Sarepta, Ed asked Henri to be an Advisor to the CEO which was a wonderful experience having one of the most experienced Biotech industry leaders provide advice and counsel. Henri would put the needs of the patients above the corporate needs and followed the montra that ‘good medicine is good business’. Ed was privileged to consider Henri as a friend in addition to a mentor.

Ed currently serves as a member of the boards of directors at Cytokinetics, Inc., Avidity Biosciences and the Massachusetts Biotechnology Council. Prior to entering the biotech industry, Ed trained in pediatrics, pediatric neurology and biochemical genetics. He was on the research staff at Massachusetts General Hospital and Tufts University Medical Center and was the chief of biochemical genetics at the Children’s Hospital of Philadelphia. He was on the pediatric neurology staff at Boston Children’s Hospital until 2021. Ed earned his B.S. in biology from Loyola University and earned his M.D. at the Loyola University Stritch School of Medicine.

Alison Lawton

Alison Lawton

Alison Lawton is currently Special Advisor to the Office of the CEO of Kaleido Biosciences, where she was previously President and CEO for two years and President & COO for one year. Alison has served as Chief Operating Officer of Aura Biosciences and OvaScience and served as a biotech consultant for various companies, including as Chief Operating Officer for X4 Pharmaceuticals (XFOR). Prior to that, Alison spent more than 20 years in various positions of increasing responsibility at Genzyme Corporation, and subsequently at Sanofi-Aventis, following its acquisition of Genzyme, including as General Manager & Senior Vice President of Genzyme Biosurgery, a $800M revenue business which included orthopedics, surgical and cell therapy & regenerative medicines.

Previously she was Senior VP Global Market Access which included Regulatory Affairs, Health Outcomes & Strategic Pricing and Public Policy. Before joining Genzyme, Alison was based in the UK with Parke-Davis, a pharmaceutical company.

Alison currently serves as a member of the board of directors of ProQR Therapeutics N.V. (PRQR), Aeglea Biotherapeutics (AGLE), X4 Pharmaceuticals (XFOR) and Magenta Therapeutics Inc. (MGTA). She previously served on the board of Kaleido Biosciences (KLDO), Verastem, Inc. (VSTM), CoLucid Pharmaceuticals, Inc. (CLCD) until its acquisition by Eli Lilly and Cubist Pharmaceuticals (CBST) until its acquisition by Merck &Co. She is past President and Chair of the Board of Regulatory Affairs Professional Society and past FDA Advisory Committee member for Cell and Gene Therapy Committee.

Areas of expertise: Regulatory strategy, product and clinical development, company building including international, and fund-raising including IPO.

John Maraganore

John Maraganore

Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®.

At Alnylam, he also led the company’s value creation strategy, building $25B in market capitalization and forming over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc., where he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory and metabolic diseases, in addition to leadership of M&A, strategy, and biotherapeutics functions.

Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company.

Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, an Executive Partner at RTW Investments, and Senior Advisor for Blackstone Life Scuences. He is also member of the Board of Directors of publicly traded companies (Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics), private companies (Hemab, TranSend, Aerium, and Versanis), and the Biotechnology Industry Organization, where he was Chair from 2017-2019 and is Chair Emeritus.

In addition, he serves on the Board of the Termeer Foundation – committed to continuing the legacy of the late Henri A. Termeer, as Chair of the n-Lorem Foundation Advisory Council – committed to meeting the needs of patients with nano-rare diseases, and on the Advisory Board of Ariadne Labs – advancing global health system innovations. John also serves as a strategic advisor to a number of innovative biotechnology companies, with a focus on mentoring CEOs in their mission to advance science and innovation for patients.

Areas of Expertise: General Management; Leadership and Strategy; Science and Clinical Development; and Communications.

Thomas P. Mathers

Thomas P. Mathers

Tom P. Mathers is the Founder, President and CEO of Allievex, a biotechnology company focused on the development of novel therapeutics for the treatment of rare pediatric neurodegenerative diseases. He is also a partner at Pappas Capital, a dedicated life science venture capital firm focused exclusively on investing in the life sciences sector across the United States and Canada.

Prior to Pappas Capital and Allievex, Tom was the President and CEO of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), which focused on the development of lasmiditan (Reyvow™) for the acute treatment of migraine headaches. Eli Lilly & Company acquired CoLucid in March 2017 in an all cash transaction for $1 billion. Prior to CoLucid, Mr. Mathers was President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery, Inc; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at Genzyme Corporation.

Tom is also currently serving as a Trustee of Butler University, 4D Molecular Therapeutics, and as co-founder and Chairman of Déclion Holdings, a biopharmaceutical company focused on the discovery and development of innovative treatments for neurodegenerative diseases. He has previously served on the Board of Directors for the Biotechnology Industry Organization for nine years, where he was active in the policy areas of capital formation, bioethics, intellectual property, and regulatory policy.

Tom earned a BS in Engineering from the United States Military Academy at West Point in 1988, where he also played football for four years. He went on to serve as a Captain in the United States Army and received several medals for his service as an AH-64 Apache helicopter pilot during the Gulf War.

Areas of Expertise: Company founding and building, R&D and pipeline strategy, partnering and business development, venture capital and fundraising, and general management.

Geoff McDonough

Geoff McDonough

Geoff McDonough is the President & Chief Executive Officer of Generation Bio. Geoff formerly served as president and chief executive officer of Swedish Orphan Biovitrum AB (Sobi) from 2011 – 2017. Prior to Sobi, he held a variety of senior roles at Genzyme Corporation, including president of Genzyme Europe and senior vice president and general manager of the global lysosomal storage disease business.

Geoff has a Bachelor of Science in biology and a Bachelor of Arts in philosophy from University of North Carolina at Chapel Hill, graduating summa cum laude in both. He obtained his doctor of medicine at Harvard Medical School and completed his residency training in internal medicine and pediatrics at Massachusetts General Hospital and Boston Children’s Hospital.

Areas of Expertise: rare disease
- company building - leadership and development - global commercialization - regulatory engagement - private and public fundraising - investor relations - patient voice

David Meeker

David Meeker

David Meeker is the Chairman, President & CEO of Rhythm Therapeutics, a biotechnology company focused on developing innovative therapies for rare genetic disorders of obesity. Dr. Meeker was formerly the President and CEO of Genzyme, a Sanofi company, a position he assumed when Genzyme merged with Sanofi in 2011. He was also a member of the Sanofi executive committee. He was most recently CEO of KSQ Therapeutics an early stage functional genomics company.

In his career with Genzyme, David held key positions of increasing responsibility beginning in the R&D organization and subsequently in operating roles, culminating in the position of Chief Operating Officer at the time of the merger. In his most recent role within Sanofi, he headed Sanofi-Genzyme, the specialty care unit with responsibility for Rare Diseases, MS, Oncology and Immunology franchises. Prior to joining Genzyme, David was the Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an assistant professor of medicine at Ohio State University. He completed his internal medicine training at Harvard’s Beth Israel Hospital and his pulmonary/critical care training at Boston University. He completed the Advanced Management Program at Harvard Business School in 2000.

David is the Chairman of the Board of Trevi Therapeutics and a member of the board at Myokardia. He also serves on the boards of the Biomedical Science Careers Program, the Network for Excellence in Health Innovation and the Dimock Center, a Boston based community health center.

Areas of Expertise: Leadership and corporate strategy; governance and board building; clinical development strategy; rare disease community building; Global expansion; business development.

Lydia Meyer-Turkson

Lydia Meyer-Turkson

Lydia Meyer-Turkson is the Global Early Innovation Partnering Leader for Oncology working out of the Boston Innovation Center.

In her role, Lydia serves as the key point of contact for the oncology therapeutic area for interactions with the Janssen R&D (JRD) leadership to ensure external innovation opportunities are centrally coordinated and strategically aligned with business priorities. Lydia joined Johnson & Johnson Innovation in January 2022 from Inari Agriculture Inc, a Flagship Ventures company. In her prior role as Vice President of Business Development at Inari, she developed, led and executed the company’s partnering strategy for its gene editing and deep learning technologies in human therapeutics. She worked closely with the Leadership Team, External Innovation, Legal and Patent colleagues to define opportunities aligned to strategic goals and build the business case for partnering.

Lydia brings 20 years of broad ranging business development experience working with R & D teams commercializing platform technologies across a range of in and out licensing transactions, M&A and research collaborations in oncology and rare disease drug discovery, biomarkers and diagnostics. She has worked in the UK, Europe and US with CEO and Executive teams in roles at Horizon Discovery plc (acquired by Perkin Elmer), Evotec GmbH and Epistem plc helping lead business growth. Lydia earned her M.Phil (Masters) in Chemistry at Cardiff University and MBA at Manchester Business School, UK and is a Fellow of the Royal Society of Chemistry and member of the Integrated Chemistry- Biology Research Committee there. Lydia is passionate about socioeconomic diversity and inclusion and has undertaken volunteer roles as reviewer for the L’Oréal Women in Science Awards Committee for Sub-Saharan Africa and the Women in Cancer Research AACR Scholarship Awards Committee.

Alan Walts

Michael R. Minogue

Mr. Michael R. Minogue has been Chairman, President and Chief Executive Officer of Abiomed (NASDAQ: ABMD) since 2004. Mr. Minogue transitioned the company’s mission to creating the field of heart and lung recovery with the acquisition and development of technologies such as Impella®, the world’s smallest heart pump, and extracorporeal membrane oxygenation (ECMO). Abiomed has been one of the fastest growing, GAAP profitable medtech companies and ranked the third best performing stock on the S&P 500 for the last decade. Abiomed has earned numerous global regulatory approvals on products and indications in the United States, Europe, Japan and other countries. Abiomed employs approximately 1,700 people with facilities in Danvers, Massachusetts, Baltimore, Maryland, Aachen and Berlin, Germany and Tokyo, Japan.

In addition to his responsibilities at Abiomed, Mr. Minogue currently serves as Chairman of the medical device industry association board of directors for AdvaMed and serves on the board for the Medical Device Innovation Consortium (MDIC). He also serves on Insulet Corporation's board of directors and was on the boards of LifeCell and Bioventus.

Before joining Abiomed, Mr. Minogue spent 11 years with General Electric Healthcare, where he held numerous leadership positions and holds three patents. Mr. Minogue also served as an officer in the U.S. Army, which included multiple distinctions including Airborne, Ranger, Desert Storm Veteran and Bronze Star. He received his Bachelor of Science degree in engineering management from the United States Military Academy at West Point and his Master of Business Administration from the University of Chicago.

Mr. Minogue cofounded the Mike and Renee Minogue Foundation and MedTechVets, a 501(c)(3) nonprofit organization that helps military veterans network with industry mentors to discover career opportunities in the medtech industry. He serves on the board of directors after serving as Chairman for 8 years. Mr. Minogue formerly served as the Chairman of the Governor’s Advisory Council on Veterans’ Services for Massachusetts and supports the Inner-City Scholarship Fund, Boys and Girls Club, and multiple educational initiatives. Mr. Minogue is married with five children and enjoys reading, mentoring, running, coaching, skiing and playing sports.

Areas of Expertise: regulatory process, cardiology, new product introduction, leadership development, strategy and marketing.

Paula Ragan

Paula Ragan

Paula Ragan has more than 20 years of experience building and leading companies in the biotechnology industry. Since 2014, Dr. Ragan has been the Chief Executive Officer and a member of the Board of Directors of X4 Pharmaceuticals in Cambridge, MA.

Previously, Paula consulted as Chief Business Officer at Lysosomal Therapeutics Inc. (LTI), an Atlas Venture portfolio company, where she led the company’s business activities. From 2007-2012, Paula held leadership roles in corporate development and operations at Genzyme/Sanofi where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation.

Paula received her PhD in Medical Engineering and Medical Physics from MIT and completed post-doctoral studies at Harvard Medical School.

Areas of Expertise: Start-up do’s and don’ts, Business/corporate development, Financing strategy, Corporate culture

Hans Schikan

Hans Schikan

Hans Schikan, PharmD, brings more than 30 years of development, commercial and leadership experience in the (bio)pharmaceutical sector, latest as CEO of Prosensa in The Netherlands, a company focusing on rare diseases, with a lead program in Duchenne Muscular Dystrophy. During his leadership, Prosensa established a collaboration with GlaxoSmithKline in 2009 and was listed on NASDAQ in 2013. The company was acquired by BioMarin early 2015.

Hans got to know Henri while working at Genzyme where he was Vice President, Marketing and Strategic Development for the rare disease portfolio. Shortly after Hans became CEO of Prosensa, Henri joined Prosensa as Strategic Adviser and mentor. Henri’s strategic guidance and personal mentorship were both inspiring and instrumental. The values which Henri stood for have become a beacon for Hans in the various board roles he became subsequently involved in. When Hans facilitated a Memorandum of Understanding by Massachusetts and The Netherlands in 2019, the signing ceremony was done with a picture of Henri as a backdrop. Hans is currently involved as board member or chairman in various listed and private biopharma companies in The Netherlands, Sweden, Belgium, Switzerland and the UK.

Hans co-founded Pharvaris, a rare disease company focusing on HAE in 2015. The company was listed on NASDAQ in 2021.

He is also member of the Top Team for the Dutch Topsector Life Sciences & Health. Finally, he was appointed Special Envoy Vaccines by the Dutch Minister of Health, Welfare and Sport.

Areas of Expertise: Company founding and building. R&D and strategic development, partnering, business development, M&A, interactions with patient organizations, venture capital, fundraising, IPO preparations, and general management. Public-private partnerships, transatlantic collaboration.

Alicia Secor

Alicia Secor

Alicia Secor is an accomplished 25+ year healthcare executive with a demonstrated track record in leading teams from product development through regulatory approval, and commercialization across multiple therapeutic areas spanning orphan and prevalent diseases.

Alicia is currently President & CEO (and member of BOD) of Atalanta Therapeutics, a privately held company focused on neurodegeneration. She also recently served as president and chief executive officer at Juniper Pharmaceuticals, Inc., a diversified public healthcare company where she led the successful turnaround strategy for the company resulting in a sale to Catalent, Inc. in August 2018.

Prior to her role at Juniper, Alicia held a number of leadership positions in the life sciences industry, including chief commercial officer at Zafgen Inc., senior vice president and chief operating officer at Synageva BioPharma Corp, and roles of increasing responsibility at Genzyme over her 15-year tenure, including serving as vice president and general manager of metabolic diseases, a global business with multiple commercial products, including two orphan drugs. Prior to Genzyme, Secor held positions at Alkermes, Inc. in business development, at Centocor, Inc. (a Johnson & Johnson Company) in clinical and commercial operations, and began her career at Pfizer Inc. as a hospital-based sales representative.

Alicia is also a member of the board of directors at GW Pharmaceuticals, plc., Orchard Therapeutics, and a board member of the Foundation for Prader-Willi Research (FPWR). Instead: Alicia is currently a director for G1 Therapeutics and Orchard Therapeutics. Formerly she served on the Board of GW Pharmaceuticals until is acquisition by Jazz Pharmaceuticals.

She received her B.S. in health administration from the University of New Hampshire and an MBA from Northeastern University.

Areas of Expertise: Commercial: from pre-launch prep to post-launch life-cycle management; Investor relations (C-Suite perspectives); Patient advocacy; Corporate culture development; Crisis leadership (navigating teams and businesses through ups, downs, and turnarounds). Company building

Craig Shimasaki

Craig Shimasaki

Craig Shimasaki is co-founder and CEO of Moleculera labs, a neuroimmunology precision medicine company focused on diagnosing and treating neuropsychiatric and behavioral disorders mediated by an autoimmune response. He has over 35 years of biotechnology industry experience, starting his career at Genentech.

Craig is a serial entrepreneur and scientist, co-founding nine companies in which he participated in taking five companies public in the U.S. and Canadian stock exchanges. His experience is in translating basic research discoveries, and establishing and building business enterprises in the therapeutic, diagnostic, and medical device arena. Craig has hands-on experience through the breadth of company development stages. He has led multiple products through the FDA approval process and is a co-inventor on several patents. His scientific background included epitope mapping for an HIV vaccine, SNP-based genetic breast cancer risk prediction biomarkers, a rapid influenza diagnostic, and therapeutic and biologics for infectious diseases and neuropsychiatric disorders.

He received his BS in Biochemistry from the University of California at Davis, his PhD in Molecular Biology from the University of Tulsa, and his MBA from Northwestern University, Kellogg School of Business. He is an Adjunct Professor and Senior Entrepreneur-in-Residence at the University of Oklahoma, Price School of Business. He has authored and edited three books “The Business of Bioscience: What Goes Into Making a Biotechnology Product”, “Biotechnology Entrepreneurship: Starting, Managing and Leading Biotech Companies”, and a 2nd edition, “Biotechnology Entrepreneurship: Leading, Managing and Commercializing Innovative Products.” His passion is to help translate scientific and medical discoveries into acutely needed products so that more patients can live healthier lives.

Areas of Expertise: Subject Matter: immunology, virology, protein biochemistry, mental illness, CNS disorders, vaccines, diagnostics, precision medicine, biologics. Entrepreneurial: aligning technology with market need, strategic planning, CEO mentoring and leadership development, investor presentations and pitches, cross-discipline team integration, defining team member characteristics and core values, Go-to-Market strategy, implementing barriers to entry.

Paula Soteropoulos

Paula Soteropoulos

Paula Soteropoulos has more than 30 years of experience in the biopharma industry in areas of drug development, manufacturing, business development, global commercialization with P&L accountability, company building and organizational development. Paula currently is Chairman of the Board of Ensoma, a company she was instrumental in launching from the venture seed stage. She also serves on the Board of Directors for uniQure, Rallybio, Kyowa Kirin North America and Chiesi USA. She is also a Strategic Advisor to 5AM Ventures. Prior, she served as the CEO and a member of the board of directors of rare disease therapeutic developer Akcea Therapeutics. Paula was the founding President and CEO in 2015 and led the company through its IPO on NASDAQ in 2017, as well as significant growth: employing over 270 staff in thirteen countries, six drugs in its portfolio with 2 rare disease drug approvals and commercial launches. Prior, she served as Senior Vice President and General Manager, Cardiometabolic and Rare Disease Businesses & Strategic Alliances at Moderna Therapeutics and worked for over 20 years at Genzyme Corporation, most recently as Vice President and General Manager, Cardiovascular, Rare Diseases. Paula credits Henri and other Genzyme mentors for their willingness to take risks on her, giving her growth opportunities in varied roles from engineering and manufacturing to leading global commercial businesses.

Paula earned her B.S. and Master’s degrees in Chemical and Biochemical Engineering from Tufts University and earned an executive management certificate from Darden School of Business, University of Virginia. She also serves on the Advisory Board for the Chemical and Biological Engineering Department of Tufts University.

Areas of Expertise: Company and culture building; New ventures; IPO and Investor relations; Rare disease development and commercialization; Global expansion; Strategic collaborations; Building a board & governance; Diversity/Female mentorship.

Jeff Albers

Dinko Valerio

Dinko Valerio is a scientist-turned-entrepreneur and the founder and former CEO of Crucell. He further co-founded Galapagos Genomics and Venture Capital firm Aescap Venture. Dinko is a mentor of entrepreneurs in which function he co-founded ProQR Therapeutics (PRQR) where he is Chairman of the Board. Dinko is also founding Chairman of the Board of Leyden Laboratories since 2020.

In 1992 Dinko was appointed professor of gene therapy at the University of Leiden, where he also received his Ph.D. with honors.

In 1993, shortly after founding Crucell (initially called IntroGene), Dinko met Henri. This resulted in a a collaboration between Genzyme and IntroGene on vector technology and virus-based products. At that time Henri joined IntroGene’s Board and became a mentor to Dinko which helped shape him from a scientist into an entrepreneur. In 2012, the two started working together again, this time as co-founders and Board members of ProQR.

Areas of Expertise: Initial formation and development of company, professional development of entrepreneurs.

Ed Kaye

Willem Van Weperen

Willem is a senior commercial leader focused on building and leading teams around the world to bring rare disease therapies to patients and to build healthcare systems for optimal care.

Most recently he was Senior Vice President International for Intercept in the liver disease area, leading the ex-US commercial business with a central team in London and affiliates in Germany, Italy, Spain, France, UK and Canada, plus distributors in other global markets. Under his leadership a passionate, engaged team grew strong digital commercial / medical capabilities. Intercept’s International organization was acquired by Advanz Pharma in June 2022.

Willem has more than 25 years of experience in the biopharmaceutical industry. During this period, he was active in the areas of R&D and commercialization, and fulfilled several leadership positions. Willem started his career in clinical research at GSK in 1993. In 1994 he joined Genzyme, where he fulfilled several medical and commercial positions. This included leadership roles for Global Marketing in the rare genetic disease business unit and as General Manager for Genzyme Netherlands. In 2009 he joined the biotech start-up company to-BBB as their CEO. With his team he brought two brain disease therapies in the clinic, raised capital, and established several pharma collaborations. Between 2014 and 2021 Willem held various commercial leadership roles for Prosensa in the Duchenne Muscular Dystrophy area, for Amicus in the Fabry and Pompe disease areas and for Myokardia in the cardiac disease area.

Willem obtained a MSc degree in biomedical sciences from Utrecht University, and an MBA degree from NIMBAS / Bradford University.

Areas of Expertise: global people and team development; commercial and launch leadership; global market expansion; international pricing and reimbursement strategy; early access; thought leader development; patient advocacy; commercial financial planning.

Alan Walts

Alan Walts

Alan Walts co-founded The Termeer Foundation and serves as its Treasurer, Secretary, and as a director. He also serves as Executive Chairman of PIC Therapeutics, Artax Biopharma and Ziknani Therapeutics. Alan is a Board Observer for Aura Biosciences, Amylyx Pharmaceuticals and Arrakis Therapeutics. He is also a US-based Venture Partner with Advent Life Sciences and on the Advisory Board of the ALS Investment Fund.

Alan was a Business Advisor to Henri Termeer from 2013 - 2017, and worked closely with Henri on founding and investing in early stage companies. He first met Henri in 1983 at Genzyme and had the remarkable good fortune to learn from Henri throughout his career at Genzyme. While demanding excellence, Henri provided regular advice, guidance, and mentoring during Walts’s career at Genzyme and thereafter. Alan has over 25 years of industry experience at Genzyme in business development, business strategy, research and development, general management, and venture capital. Prior to leaving Genzyme in 2013, he most recently managed Genzyme’s corporate venture fund, Genzyme Ventures (now Sanofi Ventures).

Alan received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the executive Program for Management Development at Harvard Business School.

Areas of Expertise: Company founding and building, R&D and pipeline strategy, partnering and business development, venture capital and fundraising, and general management.

Peter Wirth

Peter Wirth

Peter Wirth is a Venture Partner with Quan Capital Management, a global life sciences venture capital firm with offices in Shanghai, San Francisco and Cambridge. Peter also serves as Chairman of FORMA Therapeutics (Nasdaq: FMTX), a clinical-stage biopharmaceutical company developing novel therapeutics for patients with rare hematologic diseases and cancers, as Chairman of Syros Pharmaceuticals (Nasdaq: SYRS), a biotechnology company redefining the power of small molecules to control the expression of genes, and as a Director of Zai Lab (Nasdaq: ZLAB), a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world.

From 1996 until its acquisition by Sanofi in 2011, Peter was a senior executive at Genzyme, most recently serving as Executive Vice President, Legal and Corporate Development, Chief Risk Officer and Corporate Secretary. During his time at Genzyme, Wirth had senior management responsibility for the company’s legal and corporate development functions, molecular oncology division, polymer drug discovery and development division and enterprise risk management function. He was instrumental in helping build Genzyme from a small start-up to a diversified, multi-billion dollar enterprise with more than 12,000 employees in locations spanning the globe.

Prior to joining Genzyme, Peter practiced law at Palmer & Dodge LLP, where he was head of the firm’s biotechnology practice group and served as outside general counsel for Genzyme as well as numerous other biopharmaceutical companies.

Peter received his B.A. from the University of Wisconsin-Madison and his J.D. from Harvard Law School.

Areas of Expertise: Corporate financing (including venture capital and capital structures), corporate governance (including recruiting and managing a Board of Directors and executive compensation planning) and corporate transactions (including corporate partnering and M&A).

Alan Walts

James Xue

James Xue is a biotechnology industry entrepreneur and executive with 20 plus years global experience starting and building companies with commitment to transform patients’ lives. He is the Founder, Chairman & CEO of CANbridge Pharmaceuticals Inc., a biotechnology company focusing on rare disease and rare oncology based in China and the U.S. James was formerly a 10-year veteran at Genzyme where he held various global managerial and executive positions in R&D strategy, business and market development, general management and most notably the founding General Manager of Genzyme China. Today he is recognized in China for his trailblazing and leadership role in starting and building rare disease biotech. James owes his success to Henri and other Genzyme mentors who continue to inspire him to date.

James is the Co-Founder and Deputy Director General of China Alliance for Rare Disease (CARD), Deputy Director of Shanghai Foundation for Rare Disease, Vice Chair of the R&D Committee of China Pharmaceutical Innovation and Research Development Association (PHIRDA), a member of the Advisory Committee of the Joint Institute of Peking University Health Science Center and University of Michigan Medical School. He is a member of BayHelix Group and founding member of BayHelix Boston Chapter. James holds a B.S. in Pharmaceutical Chemistry from Peking University School of Pharmacy, a Ph.D. in Bioorganic Chemistry from Brown University and a M.B.A. from Darden School of Business, University of Virginia.

Areas of Expertise: Company founding and building, R&D and pipeline strategy; Cross-border partnering and business development; International fundraising; Government Affairs and NGO management

termeer logo bottom